Business
PROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in Japan
REDWOOD CITY, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a global leader in surgical
About this update from Procept Biorobotics Corporation
[{"type":"text","content":"REDWOOD CITY, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a global leader in surgical robotics, announced today that it has successfully completed the first commercial Aquablation® therapy procedures in Japan. The procedures were carried out at two premier medical institutions, in association with the 100 patient post-market surveillance study. Completing the first commercial procedures in Japan represents another important milestone in PROCEPT BioRobotics’ global expansion, highlighting the growing acceptance and recognition of Aquablation therapy as a pioneering solution for BPH patients. Following the successful procedures at Oita University Hospital and Nihon University Itabashi Hospital, Japanese urologist Dr. Masato Fujisawa, Professor, Division of Urology, Kobe University Hospital, praised the new therapy, \"With millions of Japanese men suffering from BPH, the regulatory clearance and successful completion of Aquablation therapy procedures marks a vital development in improving patient care. Aquablation therapy's unique blend of robotic precision and reproducibility sets a new standard in BPH treatment.\" \"We view Japan as a very promising market for the adoption of Aquablation therapy, which has a long history of adopting new, innovative technologies, while prioritizing patient outcomes. Similar to our approach in the U.S., we intend to pave the way in Japan with solid clinical data and support from key opinion leaders, setting the stage for a dynamic and lasting commercial success,” said Reza Zadno, PROCEPT BioRobotics’ CEO. Dr. Shigeo Horie, Professor, Department of Urology, Juntendo University Hospital, commented, \"Traditionally, surgeons visualized the prostate through a limited cystoscopic window during BPH procedures. With Aquablation therapy, we complement that view by utilizing real-time ultrasound imaging to view the entire prostate. This, coupled with advanced planning software and automated robotic resection, enables Japanese urologists to provide a customized treatment option for every patient in a safe and effective manner. Aquablation therapy represents a significant advancement in BPH treatment, and we are excited to now offer this innovative solution to our patients.” About Aquablation TherapyAquablation therapy is the first and onl...